FI943933A0 - Menetelmä fibrinogeenireseptoriantagonistien valmistamiseksi - Google Patents

Menetelmä fibrinogeenireseptoriantagonistien valmistamiseksi

Info

Publication number
FI943933A0
FI943933A0 FI943933A FI943933A FI943933A0 FI 943933 A0 FI943933 A0 FI 943933A0 FI 943933 A FI943933 A FI 943933A FI 943933 A FI943933 A FI 943933A FI 943933 A0 FI943933 A0 FI 943933A0
Authority
FI
Finland
Prior art keywords
preparation
receptor antagonists
fibrinogen receptor
fibrinogen
antagonists
Prior art date
Application number
FI943933A
Other languages
English (en)
Swedish (sv)
Other versions
FI943933A (fi
FI106023B (fi
Inventor
John Y L Chung
David L Hughes
Dalian Zhao
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of FI943933A0 publication Critical patent/FI943933A0/fi
Publication of FI943933A publication Critical patent/FI943933A/fi
Priority to FI982545A priority Critical patent/FI107255B/fi
Application granted granted Critical
Publication of FI106023B publication Critical patent/FI106023B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FI943933A 1992-02-28 1994-08-26 Menetelmä N-(n-butyylisulfonyyli)-O-[4-(4-piperidyyli)butyyli]tyrosiinin valmistamiseksi FI106023B (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI982545A FI107255B (fi) 1992-02-28 1998-11-24 O-[4-(4-pyridyyli)butyyli]-N-butyylisulfonyyli-(L)-tyrosiini, menetelmä sen valmistamiseksi ja sen käyttö vastaavan O-[4-(4-piperidinyyli)butyyli]johdannaisen valmistamiseksi

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/843,658 US5206373A (en) 1992-02-28 1992-02-28 Process for preparing fibrinogen receptor antagonists
US84365892 1992-02-28
US9301646 1993-02-23
PCT/US1993/001646 WO1993016995A1 (en) 1992-02-28 1993-02-23 Process for preparing fibrinogen receptor antagonists

Publications (3)

Publication Number Publication Date
FI943933A0 true FI943933A0 (fi) 1994-08-26
FI943933A FI943933A (fi) 1994-10-04
FI106023B FI106023B (fi) 2000-11-15

Family

ID=25290632

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943933A FI106023B (fi) 1992-02-28 1994-08-26 Menetelmä N-(n-butyylisulfonyyli)-O-[4-(4-piperidyyli)butyyli]tyrosiinin valmistamiseksi

Country Status (25)

Country Link
US (1) US5206373A (fi)
EP (2) EP0738714B1 (fi)
JP (1) JP2674679B2 (fi)
KR (1) KR100187779B1 (fi)
CN (1) CN1050832C (fi)
AR (1) AR247878A1 (fi)
AT (1) ATE156118T1 (fi)
AU (2) AU3732293A (fi)
CA (1) CA2090509C (fi)
CZ (1) CZ283485B6 (fi)
DE (1) DE69312528T2 (fi)
DK (1) DK0558139T3 (fi)
ES (2) ES2105069T3 (fi)
FI (1) FI106023B (fi)
GR (2) GR3024965T3 (fi)
HU (2) HU226957B1 (fi)
LV (1) LV12824B (fi)
MX (1) MX9301045A (fi)
NZ (1) NZ249751A (fi)
RO (1) RO116016B1 (fi)
RU (2) RU2114105C1 (fi)
SK (1) SK281250B6 (fi)
TW (1) TW229206B (fi)
WO (1) WO1993016995A1 (fi)
YU (1) YU49077B (fi)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264813B1 (it) * 1993-07-28 1996-10-10 Oxon Italia Spa Procedimento per la preparazione di alcansolfonammidi
US5780480A (en) * 1996-02-28 1998-07-14 Merck & Co., Inc. Fibrinogen receptor antagonists
US5980951A (en) * 1996-04-10 1999-11-09 Merck & Co., Inc. Oral coated active drugs
CA2259487A1 (en) 1996-07-01 1998-01-08 Margaret Mary Faul Hypoglycemic and hypolipidemic compounds
GB9812088D0 (en) * 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
CN1330636C (zh) * 2005-09-26 2007-08-08 鲁南制药集团股份有限公司 盐酸替罗非班中间体的合成方法
CN102452975A (zh) * 2010-11-01 2012-05-16 天津康鸿医药科技发展有限公司 盐酸替罗非班中间体合成方法
CN104447509B (zh) * 2013-09-18 2016-08-24 嘉实(湖南)医药科技有限公司 一种盐酸替罗非班的制备工艺
CN108440393A (zh) * 2018-03-20 2018-08-24 成都倍特药业有限公司 替罗非班物料杂质、杂质制备及物料中杂质检测方法
CN109608387A (zh) * 2019-01-02 2019-04-12 海门慧聚药业有限公司 盐酸替罗非班的制备
CN111100066B (zh) * 2019-11-29 2021-07-30 石药集团恩必普药业有限公司 一种盐酸替罗非班中间体及盐酸替罗非班的制备方法
CN112816282B (zh) * 2020-12-29 2022-04-12 江苏慧聚药业股份有限公司 一种盐酸替罗非班的有关物质及其制备和检测方法
CN115181058A (zh) * 2021-04-01 2022-10-14 武汉武药科技有限公司 组合物及其质量控制方法
CN114315697A (zh) * 2021-12-20 2022-04-12 河北国龙制药有限公司 一种盐酸替罗非班的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB756713A (en) * 1953-07-06 1956-09-05 Ciba Ltd Substituted piperidines and process of making them
GB772516A (en) * 1953-12-22 1957-04-17 Ciba Ltd Piperidines and process of making same
GB939019A (en) * 1959-01-19 1963-10-09 Aspro Nicholas Ltd Diphenyl methane derivatives and methods for the preparation thereof
IT1062206B (it) * 1974-02-01 1983-09-20 Rotta Research Lab S P A A S Derivati della tirosina attivi sulla muscolatura liscia
DE2809377A1 (de) * 1978-03-04 1979-09-13 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2008116C (en) * 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
EP0738714A2 (en) 1996-10-23
SK102294A3 (en) 1995-04-12
EP0558139B1 (en) 1997-07-30
ES2105069T3 (es) 1997-10-16
CA2090509C (en) 1997-02-25
ATE156118T1 (de) 1997-08-15
KR100187779B1 (ko) 1999-06-01
LV12824B (en) 2002-09-20
HU226957B1 (en) 2010-03-29
TW229206B (fi) 1994-09-01
JP2674679B2 (ja) 1997-11-12
HUT70537A (en) 1995-10-30
EP0738714A3 (en) 1996-11-20
FI943933A (fi) 1994-10-04
JPH069557A (ja) 1994-01-18
US5206373A (en) 1993-04-27
GR3024965T3 (en) 1998-01-30
HU9402467D0 (en) 1994-10-28
AU3383693A (en) 1993-09-02
DE69312528D1 (de) 1997-09-04
YU13193A (sh) 1997-07-31
CZ283485B6 (cs) 1998-04-15
EP0738714B1 (en) 2001-05-02
DE69312528T2 (de) 1998-02-19
FI106023B (fi) 2000-11-15
LV12824A (en) 2002-05-20
CZ203394A3 (en) 1995-10-18
AR247878A1 (es) 1995-04-28
RU2097377C1 (ru) 1997-11-27
SK281250B6 (sk) 2001-01-18
YU49077B (sh) 2003-08-29
RU94040166A (ru) 1996-07-10
ES2156255T3 (es) 2001-06-16
DK0558139T3 (da) 1997-09-01
AU657199B2 (en) 1995-03-02
RO116016B1 (ro) 2000-09-29
HU9600658D0 (en) 1996-05-28
EP0558139A1 (en) 1993-09-01
CN1050832C (zh) 2000-03-29
WO1993016995A1 (en) 1993-09-02
CN1076441A (zh) 1993-09-22
HU217959B (hu) 2000-05-28
AU3732293A (en) 1993-09-13
KR950700252A (ko) 1995-01-16
MX9301045A (es) 1993-09-01
GR3035827T3 (en) 2001-08-31
NZ249751A (en) 1996-06-25
CA2090509A1 (en) 1993-08-29
RU2114105C1 (ru) 1998-06-27

Similar Documents

Publication Publication Date Title
DE69207351D1 (de) Fibrinogen-Rezeptor-Antagoniste
NO914429L (no) Fremgangsmaate for fremstilling av piperidinylkamfersulfonyloxytocin-antagonister
MX9101311A (es) Antagonistas receptores de fibrinogeno
FI943933A (fi) Menetelmä fibrinogeenireseptoriantagonistien valmistamiseksi
FI103666B1 (fi) Menetelmä bifenyylijohdannaisen valmistamiseksi
FI952585A0 (fi) Menetelmä bentsopyraaniyhdisteiden valmistamiseksi
FI104171B1 (fi) Menetelmä mono-N-alkyloitujen polyatsamakrosyklisten yhdisteiden valmistamiseksi
FI981709A0 (fi) Menetelmä 5-substituoitujen 2-amino-4-okso-pyrrolo/2,3-d/-pyrimidiinien valmistamiseksi
FI902316A0 (fi) Menetelmä valmistaa terapeuttisesti vaikuttavia substituoituja dihydropyrrolitsiiniyhdisteitä
FI893003A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten neplanosiinijohdannaisten valmistamiseksi
FI98461B (fi) Menetelmä terapeuttisesti käyttökelpoisten yhdisteiden valmistamiseksi
GB9320799D0 (en) Fibrinogen receptor antagonists
FI911701A (fi) Menetelmä terapeuttisesti käyttökelpoisten 2-substituoitujen alkyyli-3-karboksikarbapeneemien valmistamiseksi
FI944606A0 (fi) Menetelmä 4-pyridyyli- ja 4-piperidinyyli-imidatsolien valmistamiseksi, jotka ovat käyttökelpoisia histamiinireseptoriantagonistien synteesin välituotteina
FI100455B (fi) Menetelmä bis-indoli-alkaloidia sisältävän farmaseuttisen koostumuksen valmistamiseksi
FI892144A (fi) Menetelmä 5-C-hydroksimetyylialdoheksoosipohjaisten yhdisteiden valmistamiseksi
FI102841B1 (fi) Menetelmä mannitolin valmistamiseksi
FI903604A0 (fi) Uusi menetelmä 2-diatso-3-trisubstituoitujen silyylioksi-3-butenoaattien valmistamiseksi
PT87528A (pt) Process for the preparation of vasopressin antagonists
NO932383L (no) Fremgangsmaate for fremstilling av nye N-derivater av (fenyletyl-beta-ol)-amin
LV10425A (lv) Fibrinogena receptoru antagonisti
NO179996C (no) Brusede preparater inneholdende 5HT1-lignende reseptorantagonister
FI964117A (fi) Menetelmä uusien 1-asyylipiperidiiniyhdisteiden valmistamiseksi
FI902630A0 (fi) Menetelmä laktuloosin valmistamiseksi
FI952956A0 (fi) Menetelmä aromaattisten amiiniyhdisteiden valmistamiseksi

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: IROKO CARDIO LLC

Free format text: IROKO CARDIO LLC

MM Patent lapsed